Lorbrena (lorlatinib) - Pfizer
Miliary Brain Metastasis with Perivascular Enhancement in ALK-Positive Lung Cancer: A Rapid Recovery after Concurrent Lorlatinib and Whole-brain Radiotherapy. (PubMed, Intern Med) - Oct 1, 2026 - "Concurrent lorlatinib and whole-brain radiotherapy resulted in rapid clinical and radiological improvements. Metastatic disease should be considered in cases presenting with miliary brain enhancement and PVE, even when inflammatory or infectious conditions are suspected." 
Journal • Brain Cancer • CNS Disorders • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
http://www.ncbi.nlm.nih.gov/pubmed/42816387
 
Hironobu Hamada; Hiroshi Iwamoto; Kakuhiro Yamaguchi; Kiyofumi Shimoji; Maho Inoue; Shinjiro Sakamoto; Takeshi Masuda; Taku Nakashima; Toru Kuratomi; Yasushi Horimasu
 
Oct 1, 2026
 
Prev Next